☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
KATHERINE Study
Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)
December 6, 2018
Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study
October 15, 2018
Load more...
Back to Home